Ocata gets three new US patents for RPE therapy for macular degenerative diseases
These three new patents extend protection to include all formats and formulations of RPE cells, including suspensions and sheets of cells, for use as therapeutic agents, and the
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.